Turning off a tumor protein let immune cells reach brain tumors in mice
Original title: A dual pronged approach to cancer immune exclusion: tumor-derived LAIR-1 simultaneously drives fibrosis and blocks immune recruitment in glioma.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was done in animals, not people. Most findings at this stage never become treatments.
This was only done in mice and in cells in a lab.
The short version
In mice, blocking one protein on brain tumor cells let the immune system get in and fight the tumor.
What was studied. Researchers studied glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary, a type of brain tumor, in mice and in cells in the lab. They turned off a tumor protein called LAIR-1 and watched what happened.
What they found. Tumors with LAIR-1 built up thick, stiff tissue that kept immune cells out. When LAIR-1 was turned off in the tumor cells, that tissue broke apart. Immune cells moved in, and the mice lived longer. Adding an immune-boosting gene therapy led to 100% long-term survival in mice with a working immune system. A drug that blocks the same signal inside the cell had a similar effect.
What this means, and what it doesn't
What it could mean: This points to one reason immune treatments have not worked well for brain tumors. The tumor may build a wall that keeps immune cells out. It also names a target that drugs might be able to hit. For now it is a lead for researchers to follow, not a treatment.
What it doesn't mean: This does not mean there is a new treatment for people. The work was done in mice and in cells in a lab. No patient has been treated this way. It is not a cure, and it is not a promise of one. Many things that work in mice do not work in people. Years of testing would be needed first.
Source: PubMed, August 5, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.